This activity is intended for healthcare providers delivering care to women and their families.
After completing this activity, the participant should be better able to:
1. Describe the 2018 AHA/ACC guidelines for primary prevention of ASCVD 2
2. Discuss the potential side effects of statin medication
Estimated time to complete activity: 0.5 hours
Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty: Susan J. Gross, MD, receives consulting fees from Genoox, Inc., and has financial interest in The ObG Project, Inc.
Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.
Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from through , participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.4 contact hours.
Designated for 0.4 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Read Disclaimer & Fine PrintACOG / SMFM released a guidance update on fetal growth restriction (FGR). While there is currently no clear consensus on the definition, evaluation, and management, FGR is associated with adverse perinatal outcomes. Therefore, timely diagnosis and management is key to optimizing long term benefit. Ultrasound and fundal height measurement are important physical exam diagnostic maneuvers. Early delivery and expectant management have similar outcomes thus creating deliberate birth plans should be discussed.
Maternal Disease
Note: Nutrition, oxygenation, and cardiovascular adaptation to pregnancy (placental perfusion) are underlying maternal factor mechanisms that impact fetal growth
Fetal Factors
Placental Anomalies
Note: Placental implantation abnormalities (e.g. placental accreta spectrum, previa) not associated with FGR
Note: No current evidenced based screening methods or preventative measures such as bed rest have demonstrated improved perinatal outcomes
Note: If delivery planned <34 weeks, deliver at center with a NICU and consult MFM
Note: “Consider” magnesium sulfate (neuroprotection) if delivery <32w0d
…it may be reasonable to perform serial ultrasonography for growth assessment, although the optimal surveillance regimen has not been determined.
Maternal history of a prior SGA newborn with normal fetal growth in the current pregnancy is not an indication for antenatal fetal heart rate testing, biophysical profile testing, or umbilical artery Doppler velocimetry
Note: There is insufficient evidence to routinely administer aspirin to prevent SGA in this population
ACOG Practice Bulletin 204: Fetal Growth Restriction
Effect of Maternal Heart Disease on Fetal Growth
Maternal Fetal Medicine Specialist Locator-SMFM
Take a post-test and get CME credits
TAKE THE POST TEST
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
